Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.

Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.

Item
http://www.wikidata.org/entity/Q46057964
Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of AntiretroviralsPropargyl-Linked Antifolates Are Potent Inhibitors of Drug-Sensitive and Drug-Resistant Mycobacterium tuberculosisThe safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy.Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review.Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource SettingsInitiating antiretrovirals during tuberculosis treatment: a drug safety review.Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South Africa.Loss to follow-up and mortality among HIV-infected people co-infected with TB at ART initiation in Durban, South AfricaCYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir.Tuberculosis drug development: ensuring people living with HIV are not left behind.Immunologic response in treatment-naïve HIV-2-infected patients: the IeDEA West Africa cohort.Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis.Tuberculosis and HIV co-infection: screening and treatment strategies.Management of tuberculosis and latent tuberculosis infection in human immunodeficiency virus-infected persons.The anti-tuberculosis agents under development and the challenges ahead.Addressing Antiretroviral Therapy-Associated Drug-Drug Interactions in Patients Requiring Treatment for Opportunistic Infections in Low-Income and Resource-Limited Settings.
P2860

Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.

Item
http://www.wikidata.org/entity/Q46057964
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.
@en
Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.
@nl
type
label
Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.
@en
Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.
@nl
prefLabel
Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.
@en
Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P356
P1433
P1476
Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.
@en
P2093
P304
P31
P356
10.1097/QAD.0B013E328329148E
P407
P433
P478
P50
P577
P698